FDA Approves Edwards' Sapien M3 as First Transseptal Mitral Valve Replacement System
核心洞察
The FDA has approved Edwards Lifesciences (搜索)' Sapien M3 (搜索) system as the first fully percutaneous transseptal transcatheter mitral valve (搜索) replacement device for patients with moderate-to-severe mitral regurgitation (搜索) who are ineligible for surgery or transcatheter edge-to-edge repair.
The approval is based on results from the 299-patient ENCIRCLE trial, which demonstrated a 25.2% rate of all-cause death or hospitalization for heart failure (搜索) at one year, significantly lower than the predetermined performance goal.
Sapien M3 (搜索) is also approved for treating symptomatic mitral valve dysfunction (搜索) associated with mitral annular calcification (搜索) in patients unsuitable for surgery or TEER as assessed by a multidisciplinary heart team.
The US Food and Drug Administration has granted approval to Edwards Lifesciences (搜索)' Sapien M3 (搜索) system for transseptal transcatheter mitral valve (搜索) replacement (TMVR), marking the first FDA-approved TMVR device delivered through a fully percutaneous transseptal approach. The approval represents a significant milestone in treating patients with moderate-to-severe mitral regurgitation (搜索) who are ineligible for surgery or transcatheter edge-to-edge repair (TEER).
Expanded Treatment Indications
The Sapien M3 (搜索) system is approved for two primary patient populations. First, it addresses patients with symptomatic moderate-to-severe mitral regurgitation (搜索) who are deemed unsuitable for surgical intervention or TEER therapy. Second, the device is indicated for treating symptomatic mitral valve dysfunction (搜索) associated with mitral annular calcification (搜索) (MAC) in patients who are not candidates for surgery or TEER as determined by a multidisciplinary heart team.
This approval differentiates Sapien M3 (搜索) from Abbott's Tendyne (搜索) system, which received FDA approval earlier this year for TMVR but requires a transapical delivery approach. The Tendyne device is indicated for patients with moderate-to-severe mitral regurgitation (搜索), severe mitral stenosis (搜索), or moderate mitral regurgitation with moderate-or-greater mitral stenosis caused by MAC who are unsuitable for surgery and have anatomy unfavorable for TEER.
Clinical Evidence Supporting Approval
The FDA's decision is based on one-year results from the single-arm ENCIRCLE trial, which enrolled 299 patients with a median age of 77 years, 49% of whom were female. Most participants presented with secondary mitral regurgitation (搜索). The trial results were presented at TCT 2025 and published in the Lancet.
The primary endpoint demonstrated a 25.2% rate of all-cause death or hospitalization for heart failure (搜索) at one year, which was significantly lower than the performance goal established at the study's initiation. Beyond the primary endpoint, patients experienced meaningful clinical improvements across multiple measures, including NYHA functional class, quality of life scores, and 6-minute walk distance. The trial also demonstrated significant elimination of mitral regurgitation (搜索) following the procedure.
Technical Innovation and Procedure
The Sapien M3 (搜索) system employs a two-step procedural approach that distinguishes it from other mitral valve (搜索) interventions. The procedure begins with the delivery of a dock, followed by the deployment of a valve to completely replace the mitral valve. This transseptal approach offers a fully percutaneous option for patients who previously had limited treatment alternatives.
According to Daveen Chopra, Edwards' vice president of transcatheter mitral and tricuspid therapies, the addition of a valve replacement option could extend treatment to new patient populations who have not been adequately addressed by existing therapeutic approaches. This expansion of treatment options addresses a significant unmet medical need in patients with mitral regurgitation (搜索) who are not candidates for conventional surgical or minimally invasive repair techniques.
Clinical Impact and Patient Population
Mitral regurgitation (搜索) occurs when the valve between the left heart chambers fails to close completely, allowing blood to leak backward through the valve. This condition can significantly impact patient quality of life and cardiovascular outcomes, particularly in elderly patients who may not be suitable candidates for open-heart surgery.
The approval of Sapien M3 (搜索) provides clinicians with a new therapeutic option for managing complex mitral valve (搜索) disease, particularly in patients with challenging anatomy or comorbidities that preclude other interventional approaches. The transseptal delivery method may offer advantages in terms of procedural risk and recovery compared to transapical approaches, though direct comparative studies have not been conducted.